EUVIMEDEUVIMED entdecken
Crossref

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis

Arshdeep Singh iD, Arshia Bhardwaj, Riya Sharma, Dharmatma Singh, Devanshi Jain, Namita Bansal, Gursimran Singh Kochhar, Vandana Midha, Ajit Sood

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Arshdeep Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India. Hauptthemen laut MEDLINE: Piperidines, Colitis, Ulcerative, Pyrimidines, Azathioprine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal maintenance therapy for patients with acute severe ulcerative colitis (ASUC) remains unclear.

Aim

To evaluate the efficacy of azathioprine and tofacitinib in maintaining remission in patients with ASUC who respond to intravenous corticosteroids.

Methods

This propensity score–matched, retrospective cohort study evaluated the effectiveness and safety of azathioprine and tofacitinib as maintenance therapies in adult patients with ASUC responding to intravenous corticosteroids. We recorded rehospitalisation, corticosteroid reuse, therapeutic escalation, and colectomy. The primary endpoint was cumulative event‐free survival at 1 year. Adverse events were documented in both treatment arms.

Results

We included 115 patients in the final analysis (median age: 38 years [IQR: 28–49]; 54 females [46.95%]; 65 on azathioprine, 50 on tofacitinib). The cumulative probability of event‐free survival at 1 year was 44.0% with azathioprine and 75.0% with tofacitinib (log‐rank p = 0.01). Rates of rehospitalisation (15.4% v. 0%; p = 0.003) and therapeutic escalation (13.8% v. 2.0%; p = 0.02) were significantly greater in the azathioprine group. More patients receiving tofacitinib achieved symptomatic remission (40.0% v. 23.1%; p = 0.05), and combined symptomatic and biomarker remission (22.0% v. 16.9%; p = 0.49) at 1 year than those receiving azathioprine. Adverse events were reported in 55 patients (47.8%). No patients in either group required discontinuation of therapy due to adverse events.

Conclusion

Tofacitinib is more effective than azathioprine as maintenance therapy for steroid‐responsive ASUC at 1 year.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesColitis, UlcerativePyrimidinesAzathioprineAdrenal Cortex HormonesImmunosuppressive AgentsHumansFemaleAdultMaleRetrospective StudiesMiddle AgedTreatment OutcomeMaintenance ChemotherapyAcute DiseasePropensity ScoreSeverity of Illness Index

Stichwörter der Autor:innen

acute severe ulcerative colitisazathioprineprednisolonetofacitinibulcerative colitis

Substanzen

tofacitinibPiperidinesPyrimidinesAzathioprineAdrenal Cortex HormonesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
  • Research Associate, Digestive Diseases Care Foundation, Ludhiana, India.
  • Research and Development Centre, Dayanand Medical College and Hospital, Ludhiana, India.
  • Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Department of Internal Medicine, Dayanand Medical College and Hospital, Ludhiana, India.

ORCID-Profile: Arshdeep Singh

Zitieren

APA

Singh, A., Bhardwaj, A., Sharma, R., Singh, D., Jain, D., Bansal, N., Kochhar, G. S., Midha, V., & Sood, A. (2025). Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70246

Vancouver

Singh A, Bhardwaj A, Sharma R, Singh D, Jain D, Bansal N, et al. Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70246

BibTeX
@article{Singh2025,
  author = {Singh, Arshdeep and Bhardwaj, Arshia and Sharma, Riya and Singh, Dharmatma and Jain, Devanshi and Bansal, Namita and Kochhar, Gursimran Singh and Midha, Vandana and Sood, Ajit},
  title = {Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70246}
}
Kostenlos starten →